FDA WARNING_LETTER - www.usmedschoice.com - October 06, 2025

The U.S. Food and Drug Administration (FDA) issued a Warning Letter to www.usmedschoice.com on October 6, 2025, after reviewing its website. The FDA found the company is unlawfully selling unapproved and misbranded prescription drugs, including opioids, benzodiazepines, and Schedule II stimulants, to U.S. consumers over the internet. These actions violate sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which prohibit the introduction of unapproved new drugs and misbranded products into interstate commerce.

The FDA emphasized the severe public health risks associated with the easy online availability of these substances, citing concerns about addiction, abuse, overdose, and dangerous polysubstance use. Unapproved drugs lack FDA oversight and do not carry the necessary assurances of safety and effectiveness, potentially being contaminated, counterfeit, or containing incorrect ingredients. To protect public health, the FDA requires www.usmedschoice.com to immediately cease offering any unapproved and misbranded drugs for sale to U.S. consumers.